# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Li Watsek reiterates Kura Oncology (NASDAQ:KURA) with a Overweight.
JMP Securities analyst Reni Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $32 price...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $32 price t...
Cantor Fitzgerald analyst Li Watsek reiterates Kura Oncology (NASDAQ:KURA) with a Overweight.
Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $37 price target.
Stifel analyst Bradley Canino maintains Kura Oncology (NASDAQ:KURA) with a Buy and lowers the price target from $28 to $26.
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.63)...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $32 price t...